JNJ Headlines | Johnson & Johnson Common Stock Stock

Dow

0.06% Nasdaq

0.01%

Johnson & Johnson (JNJ)

-NYSE

86.82 0.39(0.45%) May 24, 4:01PM EDT|After Hours : 86.75 0.07 (0.08%) May 24, 4:54PM EDT

Add to Portfolio

Headlines

Get Headlines for:

Friday, March 8, 2013

FDA Turns Down J&J's Bid for Expanded Xarelto Useat Motley Fool (Fri, Mar 8)
1 Way to Prevent Cancer Todayat Motley Fool (Fri, Mar 8)
Damages awarded in J&J's DePuy hip implant caseAP (Fri, Mar 8)
Elan to start share buyback next weekat Reuters (Fri, Mar 8)
Is This Cancer Drug Really a Vaccine?at Motley Fool (Fri, Mar 8)
Investing in a Cheap Lifeat Motley Fool (Fri, Mar 8)
Johnson & Johnson Could Tap The Huge Diabetes Market With New Drug Approvalat Seeking Alpha (Fri, Mar 8)
Vivus investor prepares for proxy fightAP (Fri, Mar 8)
US STOCKS-Wall St climbs on jobs, S&P up for 9th week out of 10at Reuters (Fri, Mar 8)
The Investor's Best Health Care Stock in the Dowat Motley Fool (Fri, Mar 8)
Dissident shareholders seek overhaul of Vivus boardat bizjournals.com (Fri, Mar 8)
[$$] Jury Awards $8.3 Million Over J&J Hip Implantsat The Wall Street Journal (Fri, Mar 8)
News Summary: J&J stops selling some K-Y JellyAP (Fri, Mar 8)
UPDATE 3-Jury orders J&J unit to pay $8.3 mln in metal hip trialat Reuters (Fri, Mar 8)
CORRECTS: Jury awards $8.3 million in hip implant suit against Johnson & Johnson's DePuy unitAP (Fri, Mar 8)
J&J recalls, stops selling 3 versions of K-Y JellyAP (Fri, Mar 8)
Symmetry Boosts Bookwalter LineZacks (Fri, Mar 8)
UPDATE 1-Jury orders J&J unit to pay $8.3 mln in metal hip trialat Reuters (Fri, Mar 8)
Jury awards damages in Johnson & Johnson hip caseAP (Fri, Mar 8)
LA jury awards $8 million-plus in hip implant suit against Johnson & Johnson, DePuy unitAP (Fri, Mar 8)
LA jury orders J&J unit to pay $8.3 mln in first metal hip trialat Reuters (Fri, Mar 8)
J&J Must Pay $8.3 Million Over Defective Hip, Jury Saysat Bloomberg (Fri, Mar 8)
Is This Great Stock Trading for a Great Price?at Motley Fool (Fri, Mar 8)
There Is Potential in This Highly Lucrative Industryat Motley Fool (Fri, Mar 8)
Johnson & Johnson Could Tap The Huge Diabetes Market With New Drug Approvalat Forbes (Fri, Mar 8)

Older Headlines - Most Recent Headlines

Add JNJ News to My Yahoo!

Quotes are real-time for NASDAQ, NYSE, and NYSE MKT. See also delay times for other exchanges. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off.

Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and Morningstar Index data provided by Morningstar, Inc.

Yahoo! Finance

Breaking News Visit Yahoo! News for the latest.

Search for share prices

More On JNJ

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Johnson & Johnson (JNJ)

Friday, March 8, 2013